1. Home
  2. VRTX vs SBUX Comparison

VRTX vs SBUX Comparison

Compare VRTX & SBUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • SBUX
  • Stock Information
  • Founded
  • VRTX 1989
  • SBUX 1971
  • Country
  • VRTX United States
  • SBUX United States
  • Employees
  • VRTX N/A
  • SBUX N/A
  • Industry
  • VRTX EDP Services
  • SBUX Restaurants
  • Sector
  • VRTX Technology
  • SBUX Consumer Discretionary
  • Exchange
  • VRTX Nasdaq
  • SBUX Nasdaq
  • Market Cap
  • VRTX 115.6B
  • SBUX 98.7B
  • IPO Year
  • VRTX 1991
  • SBUX 1992
  • Fundamental
  • Price
  • VRTX $398.10
  • SBUX $89.30
  • Analyst Decision
  • VRTX Buy
  • SBUX Buy
  • Analyst Count
  • VRTX 24
  • SBUX 26
  • Target Price
  • VRTX $496.76
  • SBUX $101.20
  • AVG Volume (30 Days)
  • VRTX 2.5M
  • SBUX 11.4M
  • Earning Date
  • VRTX 08-04-2025
  • SBUX 07-29-2025
  • Dividend Yield
  • VRTX N/A
  • SBUX 2.76%
  • EPS Growth
  • VRTX N/A
  • SBUX N/A
  • EPS
  • VRTX 14.07
  • SBUX 2.31
  • Revenue
  • VRTX $11,418,800,000.00
  • SBUX $36,689,300,000.00
  • Revenue This Year
  • VRTX $10.40
  • SBUX $4.04
  • Revenue Next Year
  • VRTX $10.63
  • SBUX $6.20
  • P/E Ratio
  • VRTX $28.24
  • SBUX $38.34
  • Revenue Growth
  • VRTX 10.46
  • SBUX 0.58
  • 52 Week Low
  • VRTX $362.50
  • SBUX $75.50
  • 52 Week High
  • VRTX $519.88
  • SBUX $117.46
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 43.02
  • SBUX 41.95
  • Support Level
  • VRTX $388.93
  • SBUX $88.11
  • Resistance Level
  • VRTX $400.94
  • SBUX $93.58
  • Average True Range (ATR)
  • VRTX 12.48
  • SBUX 1.79
  • MACD
  • VRTX 1.47
  • SBUX -0.34
  • Stochastic Oscillator
  • VRTX 72.97
  • SBUX 8.61

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About SBUX Starbucks Corporation

Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 40,000 stores across more than 80 countries at the end of March 2025. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.

Share on Social Networks: